Paeds SAQs · fetal-neonatal-and-perinatal
Retinopathy of prematurity
Short-answer questions on ROP screening, classification, and the Type 1 treatment decision.
On this page
Study tools
Target exams
Question 1 (10 marks)
a) Define the screening criteria for retinopathy of prematurity and state when the first examination should occur. (4 marks) Screening is offered to infants with a gestational age of 30 weeks or less or a birth weight of 1500 g or less, with some guidelines adding selected unstable infants with a higher gestational age or birth weight [2]. The first retinal examination should be performed at 31 weeks postmenstrual age or 4 weeks of chronological age, whichever is later [2].
b) Describe the three axes used to classify ROP and define plus disease. (3 marks) ROP is classified by zone, stage, and the presence of plus disease [4]. The zones are concentric circles centred on the optic disc: Zone I is posterior with a radius twice the disc-to-fovea distance, Zone II extends to the nasal ora, and Zone III is the temporal crescent [4]. Plus disease is venous dilation and arteriolar tortuosity of the posterior retinal vessels greater than or equal to the standard published photograph [4].
c) This infant's findings (Zone II stage 3 with plus) meet Type 1 criteria. Outline the management. (3 marks) This infant has Type 1 ROP, which requires treatment within 72 hours [1]. The options are laser photocoagulation of the avascular retina or intravitreal anti-VEGF therapy, chosen on the basis of zone, the infant's systemic state, and the reliability of follow-up [1]. After treatment the infant needs close surveillance for recurrence or reactivation, particularly if anti-VEGF is used [3].
References4ShowHide
- [1]Early Treatment for Retinopathy of Prematurity Cooperative Group Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial Arch Ophthalmol, 2003.PMID 14662586
- [2]Fierson WM Screening Examination of Premature Infants for Retinopathy of Prematurity Pediatrics, 2018.PMID 30478242
- [3]Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity N Engl J Med, 2011.PMID 21323540
- [4]Chiang MF, Quinn GE, Fielder AR, et al International Classification of Retinopathy of Prematurity, Third Edition Ophthalmology, 2021.PMID 34247850